A research analysis by Capital market business BP Equities Private Limited revealed that many domestic-focused companies are expected to reach mid-teen growth in 2024, driven by a focus on new product launches, higher volume growth, and expanding demand for both generics and branded pharmaceuticals.

Details on Pharma companies with a domestic emphasis hope to launch new products in 2024 and achieve mid-teen growth

The pharmaceutical industry has seen signs of improvement recently, and the research attributes this trend to improved performance in the US generics market, strong performance in branded markets, reduction in raw material costs, and gains in market share from recently introduced medicines. These elements have made a substantial contribution to the high profits of indigenous pharmaceutical companies.

The survey underscored that pharmaceutical corporations have deliberately augmented their footprint in chronic medicines, prioritised the launch of novel products, and dabbled in novel therapies to leverage market prospects.

Additionally, top-line growth is anticipated for Active Pharmaceutical Ingredient (API) firms undergoing capital expenditure (capex), with 20–30% operating margins sustained in 2024 by a healthy product mix and softening input costs. 

The post Pharma companies with a Domestic Emphasis Hope to launch new products in 2024 and achieve mid-teen growth appeared first on SomMarketer.